Pfizer follows The EFPIA Code of Practice for the interactions with Patient Organizations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to Healthcare Professionals (HCPs) and the interactions with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and Patient Organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical principles of professionalism and responsibility. This Code applies to all types of communication and interaction (traditional and digital). In 2019, EFPIA consolidated its three EFPIA Codes (HCP - PO - Disclosure) into one simplified Code to better promote the common understanding of the Code by stakeholders and the general public aiming to improve adherence to the Code.

Pfizer has been at the forefront of industry transparency efforts and we fully support the Code and its aims of enhancing transparency and ensuring that relationships between the pharmaceutical industry and Patient Organisations take place in the most open and ethical manner, in full recognition of the independence of POs.

Financial support, such as through educational grants to support - giving full independence - an organisation's core activities or for specific projects, only forms one aspect of our relationship with POs.

Increasingly, we are building relationships with POs who are interested in working collaboratively with us to find new solutions to old problems. We are proud to work with many POs, including those listed below, and our partnerships are open and transparent. These are two-way relationships – we learn from each other, and our common viewpoint is that healthcare, to be effective, should be patient-centred.

The below lists contain information on the support Pfizer has provided to national, European-level and international POs. It follows the standards set out in the EFPIA Code of Practice.

Methodology Note on EFPIA Patient Organisation Reporting

Pfizer Support to European and International Patient Organisations in 2019

European & International (PDF)
Austria (PDF)
Belarus (No transfer of value to patient organisations in 2019)
Belgium
Bosnia and Herzegovina (PDF)
Bulgaria (PDF)
Croatia (PDF)
Czechia (PDF)
Denmark (PDF)
Estonia (PDF)
Finland
France  (Donations and expenses PDF)  (Partnerships and benefits PDF)
Germany(PDF)
Greece, Cyprus & Malta (PDF)
Hungary (PDF)
Iceland (No transfer of value to patient organisations in 2019)
Ireland (PDF)
Italy (PDF)
Lithuania (PDF)
Latvia (No transfer of value to patient organisations in 2019)
Luxembourg (Transfers of value to European-level organisations based in Luxembourg included in European & International disclosure)
Netherlands (PDF)
North Macedonia (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland (PDF)
Turkey (PDF)
Ukraine (PDF)
United Kingdom (PDF)

 

 

Pfizer Support to European and International Patient Organisations in 2018

European & International (PDF)
Austria (PDF)
Belarus (No funding to patient organisation in 2018)
Belgium
Bulgaria (PDF)
Croatia (PDF)
Czechia (PDF)
Denmark (PDF)
Estonia (PDF)
Finland
France  (Donations and expenses PDF)  (Partnerships and benefits PDF)
Germany(PDF)
Greece, Cyprus & Malta (PDF)
Hungary (PDF)
Iceland (No funding to patient organisation in 2018)
Ireland (PDF)
Italy (PDF)
Latvia (No funding to patient organisation in 2018)
Luxembourg (Payments to European-level organisations based in Luxembourg included in European & International disclosure)
Netherlands (PDF)
Norway
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Turkey (PDF)
Ukraine (PDF)
United Kingdom

 

Pfizer Support to European and International Patient Organisations in 2017

European & International (PDF)
Austria (PDF)
Belarus (No funding to patient organisation in 2017)
Belgium
Bulgaria (PDF)
Croatia (PDF)
Czech Republic (PDF)
Denmark
Estonia (PDF)
Finland(PDF)
France(Donations and expenses PDF)(Partnerships and benefits PDF)
Germany(PDF)
Greece, Cyprus & Malta (PDF)
Hungary (PDF)
Iceland (No funding to patient organisation in 2017)
Ireland(PDF)
Italy(PDF)
Latvia(PDF)
Lithuania (PDF)
Luxembourg
Netherlands(PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain(PDF)
Sweden
Switzerland
Turkey (PDF)
United Kingdom(PDF)

 

Pfizer Support to European and International Patient Organisations in 2016

European & International(PDF)
Austria(PDF)
Belarus (No funding to patient organisation in 2016)
Belgium & Luxembourg (Flemish Language) (French Language) (PDF)
Bulgaria (PDF)
Croatia (PDF)
Czech Republic (PDF)
Denmark
Estonia (PDF)
Finland(PDF)
France(Grants PDF, Partnerships PDF)
Germany(PDF)
Greece, Cyprus & Malta (PDF)
Hungary (PDF)
Iceland (PDF)
Ireland(PDF)
Italy (PDF)
Latvia(PDF)
Lithuania (PDF)
Netherlands(PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Serbia (PDF)
Spain(PDF)
Sweden
Switzerland
Turkey (PDF)
United Kingdom(PDF)

 

Pfizer Support to European and International Patient Organisations in 2015

European & International (PDF)
Austria(PDF)
Belarus (No funding to patient organisations in 2015)
Belgium & Luxembourg (Flemish Language)(French Language)(PDF)
Bulgaria (PDF)
Croatia (PDF)
Czech Republic (PDF)
Denmark(PDF)
Estonia (PDF)
Finland(PDF)
France (PDF)
Germany(PDF)
Greece & Cyprus (PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2015)
Ireland(PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding to patient organisations in 2015)
Netherlands(PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
Turkey (PDF)
United Kingdom(PDF)

Hospira became part of Pfizer in 2015. Funding to European patient organisations from Hospira prior to Hospira’s integration into Pfizer is declared here. (PDF)

 

Pfizer Support to European and International Patient Organisations in 2014

European & International (PDF)
Austria(PDF)
Belgium & Luxembourg (PDF)
Bulgaria (PDF)
Croatia (PDF)
Cyprus (No funding provided to patient organisations in 2014)
Czech Republic (PDF)
Denmark(PDF)
Estonia (PDF)
Finland(PDF)
France (PDF)
Germany(PDF)
Greece (PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2014)
Ireland(PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2014)
Netherlands(PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
(PDF)
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2013

European-Level Organisations (PDF)
Austria(PDF)
Belgium (Flemish Language)(French Language)(PDF)
Bulgaria (PDF)
Czech Republic (PDF)
Croatia (PDF)
Cyprus (No funding provided to patient organisations in 2013)
Denmark(PDF)
Estonia (PDF)
Finland(PDF)
France(PDF)
Germany(PDF)
Greece (PDF)
Hungary(PDF)
Iceland (No funding provided to patient organisations in 2013)
Ireland(PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2013)
Netherlands(PDF)
Norway (PDF)
Poland(PDF)
Portugal (PDF)
Romania (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain(PDF)
Sweden
Switzerland
Turkey (PDF)
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2012

European & International (PDF)
Austria(PDF)
Belgium and Luxembourg(PDF)
Bulgaria (PDF)
Czech Republic (PDF)
Croatia (PDF)
Denmark(PDF)
Estonia (PDF)
Finland(PDF)
France(PDF)
Germany(PDF)
Greece and Cyprus(PDF)
Hungary (PDF)
Iceland (PDF)
Ireland(PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2012)
Netherlands(PDF)
Norway(PDF)
Poland (PDF)
Portugal(PDF)
Romania (PDF)
Serbia (No funding provided to patient organisations in 2012)
Slovakia (PDF)
Slovenia (PDF)
Spain(PDF)
Sweden
Switzerland
Turkey (No funding provided to patient organisations in 2012)
United Kingdom(PDF)

 

Pfizer Support to European and International Patient Organisations in 2011

European & International (PDF)
Austria(PDF)
Belgium and Luxembourg(PDF)
Bulgaria (PDF)
Czech Republic(PDF)
Croatia (PDF)
Denmark(PDF)
Estonia (PDF)
Finland(PDF)
France(PDF)
Greece and Cyprus(PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2011)
Ireland(PDF)
Italy(PDF)
Latvia (No funding provided to patient organisations in 2011)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2011)
Netherlands(PDF)
Norway(PDF)
Poland (PDF)
Portugal(PDF)
Romania (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
Turkey (No funding provided to patient organisations in 2011)
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2010

European & International (PDF)
Austria (PDF)
Belgium and Luxembourg(PDF)
Bulgaria (PDF)
Croatia (PDF)
Denmark (PDF)
Estonia (No funding provided to patient organisations in 2010)
Finland(PDF)
France (PDF)
Germany (PDF)
Greece and Cyprus(PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2010)
Ireland
Italy (PDF)
Latvia (No funding provided to patient organisations in 2010)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2010)
Netherlands (PDF)
Norway(PDF)
Portugal(PDF)
Romania (PDF)
Slovakia(PDF)
Spain (PDF)
Sweden
Switzerland
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2009

European & International (PDF)
Austria (PDF)
Belgium and Luxemburg (PDF)
Bulgaria (PDF)
Estonia (PDF)
Finland (PDF)
France (PDF)
Germany (PDF)
Greece and Cyprus (PDF)
Iceland (PDF)
Italy (PDF)
Netherlands (PDF)
Norway (PDF)
Portugal(PDF)
Slovakia(PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
United Kingdom (PDF)